Dear Reader :

This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, covers an eclectic mix of stories including what to expect in the world of biotech financing and the upcoming spin-off of Sandoz.

We tell you why biotech investors are becoming more careful about where they park their money while Sandoz CEO Richard Saynor talks about how he expects to keep the business ‘driving’, amid the upcoming separation from parent company Novartis.

There’s also an interesting piece on whether CAR-NK cell therapies could potentially outshine traditional CAR-Ts for the treatment of some cancers.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA


alt_text Perspective from Industry Leaders
alt_text alt_text
Rest In Peace SPACs And Pseudo-Platforms: What Lies Ahead For Biotechs Going Public In 2023 Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers

Panelists at the BIO CEO and Investor Conference foresee some changes coming as biotech investors become more judicious about where...
 

In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation....
 
alt_text LICENSING & COLLABORATION AGREEMENTS
alt_text alt_text
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing Capitainer Positions Its qDBS Technology As Catch-All Blood Testing Solution With AstraZeneca

Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes...

The Swedish company has tweaked its dried blood spot sampling technology so that it can produce quantitative results with samples processed....
alt_text NEXT GEN: R&D
alt_text US FDA Eyes Project Orbis-Type Approach For Cell And Gene Therapies
The Cancer Cell Therapy Showdown: CAR-Ts Versus CAR-NKs US FDA Eyes Project Orbis-Type Approach For Cell And Gene Therapies

Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs....
 

A process in which the FDA coordinates reviews with other regulators would allow for better leveraging of global patient populations with ultra-rare...
alt_text CLINICAL TRIALS
alt_text alt_text
Decentralized Clinical Trials ‘No Longer A Leap Of Faith’ Experts Want To Drop Confusing Terminology For Decentralized Clinical Trials

This second segment of a two-part Pink Sheet article on decentralized clinical trials looks at ensuring that staff at study sites are on onboard... 

A new scientific paper drawn up by experts on behalf of the EU public-private Trials@Home project discusses the pros and cons of various...
Citeline Contact

Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India

Mobile: +91 994 5273146
Email: poornachandra.tejasvi@informa.com
Client Services: clientservices@pharmaintel.informa.com
 
IPA Contact

Direct: +91 022 2610 9281
Email: info@ipa-india.org
alt_text alt_text alt_text